Drug Trial Radar · NCT06110338
Safety and Tolerance Study of IBI355 in Health Volunteers
Last checked: Nov 19, 2026Latest source record: Oct 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Oct 30, 2023
Primary completion
Sep 20, 2024
Study completion Sep 23, 2024
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 31, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is being done to find out if IBI355 is safe and tolerance in health volunteers. The study will test increasing single doses of IBI355 given to adult health volunteers. The goal is to confirmed the safety of the highest dose of IBI355 or to find out the highest dose of IBI35 that can be given to health volunteer that dose not cause unacceptable side effects. Different dose regimens will be evaluated. The pharmacokinetics and ADA of IBI355 will also be evaluated.
Conditions
- Healthy Subjects
Interventions
placeboDrug
placebo iv. once.
IBI355Drug
IBI355 iv. once.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of AE、SAE after receiving IBI 355Time frame: week 0-12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Aerospace Center Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.